Go to the page content

Benefits of weight loss1-5

What we cover:

The benefits of 5–10% weight loss1-5

When it comes to managing your patients with obesity, it's important to communicate that weight loss can significantly reduce the risk of developing obesity-related complications.6

Some complications are more sensitive to weight loss than others and a weight loss of as little as 5% has been shown to have significant and long-standing health benefits. However, with increasing weight loss, the benefits in improving complications increase, and additional improvements are seen with a weight loss of 5–15%, or more.1-5,7-14

Weight maintenance and its impact on health

Below is an overview showing how much weight loss and maintenance of weight loss is needed to improve some of the most prevalent weight-related complications.15

Note that outcomes will depend upon the nature of complication.
FEV1, forced expiratory volume at 1s; GERD, gastroesophageal reflux disease; HbA1c, haemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; NAFLD, non-alcoholic fatty liver disease; PCOS, polycystic ovary syndrome.

Access further information and resources about Novo Nordisk treatments

References

  1. Garvey W, et al. Endocr Pract. 2016;22(Suppl 3):1–201.
  2. Look AHEAD Research Group. Lancet Diabetes Endocrinol. 2016;4:913–921.
  3. Lean M, et al. Lancet. 2018;391:541–551.
  4. Benraoune F, Litwin S. Curr Opin Cardiol. 2011;26:555–561.
  5. Sundström J, et al. Circulation. 2017;135:1577–1585.
  6. Markovic TP, et al. Obes Res Clin Pract. 2022;16:353–363.
  7. Knowler WC, et al. N Engl J Med. 2002;346:393–403.
  8. Wing RR, et al. Diabetes Care. 2011;34(7):1481–1486.
  9. Dattilo AM, Kris-Etherton PM. Am J Clin Nutr. 1992;56(2):320–328.
  10. Coggon D, et al. Obes Relat Metab Disord. 2001;25(5):622–627.
  11. Christensen R, et al. Ann Rheum Dis. 2007;66(4):433–439.
  12. Zelber-Sagi S, Godos J, Salomone F. Therap Adv Gastroenterol. 2016;9(3):392–407.
  13. Glass LM, et al. Dig Dis Sci. 2015;60(4):1024–1030.
  14. Ryan D, Yockey S. Curr Obes Rep. 2017;6:187–194.
  15. Schutz DD, et al. Obes Facts. 2019;12(1):40–66.
Was this valuable for you?
 

Related articles

You are now leaving Rethink Obesity®

 

The site you are entering is not the property of, nor managed by, Novo Nordisk. Novo Nordisk assumes no responsibility for the content of sites not managed by Novo Nordisk. Furthermore, Novo Nordisk is not responsible for, nor does it have control over, the privacy policies of these sites.

Go to page

The information on this website is intended for healthcare professionals. If you are a healthcare professional and have not received the password, please e-mail Novo Nordisk Medical Information at nzlccc@novonordisk.com 

The password is incorrect. If you are a healthcare professional, please contact nzlccc@novonordisk.com for the password